ROONGNAPA KHAMPANG1,2, SAWITRI ASSANANGKORNCHAI1 & YOT TEERAWATTANANON2 1Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, HatYai, Songkhla, Thailand, and 2Health Intervention and Technology Assessment Program, Department of Health, Ministry of Public Health, Nonthaburi, Tha

Katharina Kieslich1,*, Jesse B. Bump2 , Ole Frithjof Norheim3 , Sripen Tantivess4 and Peter Littlejohns1 1 Faculty of Life Sciences & Medicine, Division of Health and Social Care Research, King’s College London, London, UK 2 Department of Global Health and Population, Harvard T. H. Chan School o

GIULIA GRECOa,*, PAULA LORGELLYb and INTHIRA YAMABHAIc a London School of Hygiene & Tropical Medicine, London, UK b Centre for Health Economics, Monash University, Melbourne, Victoria, Australia c Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Bangko

Abstract Thailand is encountering challenges to introduce the high-cost sofosbuvir for chronic hepatitis C treatment as part of the Universal Health Care’s benefit package. This study was conducted in respond to policy demand from the Thai government to assess the value for money and budget impac

Abstract Background Antimicrobial resistance (AMR) is accelerated by the widespread and often indiscriminate use of antimicrobials in humans, animals, and the environment. In 2015, the World Health Organization recognised AMR as one of the top ten global health threats, due to its potential to n

Introduction Genetic disorders in children contribute to acute hospitalizations and mortality. Early diagnosis is critical for better outcomes but difficult to achieve due to atypical presentations for thousands of potential genetic diseases. Next-generation sequencing (NGS) is a precision

Abstract Background and Objectives The Health Intervention and Technology Assessment Program was commissioned to conduct a cost–utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 and 3b. The findings from this assessment are to support the decision-m

Abstract Cardiovascular disease risk assessment Pritaporn Kingkaew*, Tanunya Koopitakkajorn*, Patsri Srisuwan**, Sitaporn Youngkong*, Sripen Tantivess*, and Yot Teerawattananon* *Health Intervention and Technology Assessment Program, Ministry of Public Health, **Outpatient and Family Medicine

Abstract Disease prioritization for inclusion into Thailand’s population-based screening benefit package Sitaporn Youngkong*, Patsri Srisuwan†, Tanunya Koopitakkajorn*, Pritaporn Kingkaew*, Lily Ingsrisawang‡, Det Kedcham§, Sripen Tantivess*, Kanitta Bundhamcharoen#, Yot Teerawattananon* *He

Abstract Population-based screening for nephrosis, nephritis and renal stone in Thailand Patsri Srisuwan*, Tanunya Koopitakkajorn†, Det Kedcham‡, Pritaporn Kingkaew†, Sitaporn Youngkong†, Sripen Tantivess†, and Yot Teerawattananon† *Outpatient and Family Medicine Department, Phramongkutklao Ho